P/E ratio for VBI Vaccines (VBIV)
P/E ratio as of May 2024 (TTM): -0.0422
According to VBI Vaccines 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0422272. At the end of 2022 the company had a P/E ratio of -0.8879.
P/E ratio history for VBI Vaccines from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.8879 | -89.76% |
| 2021 | -8.67 | -33.82% |
| 2020 | -13.1 | 327.02% |
| 2019 | -3.07 | 85.92% |
| 2018 | -1.65 | -66.01% |
| 2017 | -4.85 | 12.7% |
| 2016 | -4.31 | 992.98% |
| 2015 | -0.3939 | -92.87% |
| 2014 | -5.53 | -50.21% |
| 2013 | -11.1 | 62.22% |
| 2012 | -6.84 | 76.54% |
| 2011 | -3.88 | -83.26% |
| 2010 | -23.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Onconova Therapeutics ONTX | -0.9953 | 2,257.01% | 🇺🇸 USA |
 Curis CRIS | -1.65 | 3,809.80% | 🇺🇸 USA |
 Myriad Genetics MYGN | -6.32 | 14,872.27% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.